



e-ISSN: 2319-8753 | p-ISSN: 2347-6710

# IJRSET

International Journal of Innovative Research in  
**SCIENCE | ENGINEERING | TECHNOLOGY**



# INTERNATIONAL JOURNAL OF INNOVATIVE RESEARCH

IN SCIENCE | ENGINEERING | TECHNOLOGY

Volume 13, Issue 12, December 2024

**ISSN** INTERNATIONAL  
STANDARD  
SERIAL  
NUMBER  
INDIA

**Impact Factor: 8.524**

9940 572 462

6381 907 438

[ijirset@gmail.com](mailto:ijirset@gmail.com)

[www.ijirset.com](http://www.ijirset.com)

# HIV and HPV Co-Infection: Epidemiological Insights and Implications for Women's Health

Dr. Nikita Pathak

Department of Biotechnology, Christian Eminent College, Indore, India

**ABSTRACT:** Human papillomavirus (HPV) is a widespread sexually transmitted infection, with at least 60% of sexually active adults experiencing a genital HPV infection at some point in their lifetime. Studies have consistently shown that HPV infections are detected more frequently in women who are HIV-seropositive than in their HIV-negative counterparts. Approximately 58% of a large group of women infected with HIV, as part of the Women's Interagency HIV Study ongoing since 1994, tested positive for HPV. HPV prevalence rates vary across different geographic areas. Additionally, HPV is more likely to persist or reactivate in the context of HIV infection. Women coinfecting with HIV and HPV face an accelerated risk of progression to malignancy.

In Taiwan, the number of women with HIV increased notably, with the male-to-female ratio of HIV-infected patients decreasing from 20:1 in 2003 to 7:1 in 2005. Among these HIV-positive women, 54.4% were injection drug users. A prior study revealed that female injection drug users infected with HIV often belonged to lower socioeconomic groups, engaged in risky sexual behaviors, and received minimal support from their families after multiple instances of recidivism. Among this group, 64% had never used condoms, and 88% had multiple sexual partners. To combat this crisis, Taiwan's government launched a harm reduction program in late 2005, which included a needle exchange program and methadone maintenance therapy. These measures successfully controlled the outbreak within two years.

**KEYWORDS:** HIV, HPV, Co-Infection, Antiretroviral therapy, Epidemiology, Women's health, Cervical cytology, Immunosuppression, Disease burden, Global health.

## I. INTRODUCTION

HIV prevalence is increasing worldwide, primarily because people on antiretroviral therapy (ART) are living longer. However, new infections decreased from 3.3 million in 2002 to 2.3 million in 2012. Global AIDS-related deaths peaked at 2.3 million in 2005 and dropped to 1.6 million by 2012. By 2012, approximately 9.7 million people in low- and middle-income countries had started ART. Advances in understanding latent infection mechanisms and the significance of infection reservoirs may eventually lead to a cure. Furthermore, immune activation plays a critical role in the pathogenesis of non-AIDS-related clinical events, which are major causes of morbidity and mortality among people on ART.

Breakthroughs in HIV prevention that are important to public health include male medical circumcision, ART for preventing mother-to-child transmission, and antiretrovirals for pre-exposure prophylaxis (PrEP). Research into other prevention methods, such as vaccines and vaginal microbicides, is ongoing.

HIV/AIDS remains a leading cause of death and disease burden, particularly in sub-Saharan Africa. The introduction of ART in 1996 significantly reduced HIV-related mortality. Key initiatives, including the creation of UNAIDS in 1996 and the US President's Emergency Plan for AIDS Relief (PEPFAR) in 2003, have mobilized substantial resources to combat the HIV epidemic. Between 2004 and 2015, \$109.8 billion in development assistance was provided globally, leading to a decline in HIV-related mortality in many low- and middle-income countries.

Achieving the ambitious goals of ending the AIDS epidemic by 2030 requires coordinated global efforts, including prevention programs, expanded ART coverage, and robust detection and treatment strategies. However, stagnation in health funding since 2010, coupled with limited national resources in low-income countries, presents challenges to scaling up HIV/AIDS efforts. Effective monitoring of HIV/AIDS trends at the national and regional levels is crucial for tailoring responses to the epidemic.

## II. LITERATURE SURVEY

HIV and HPV coinfections have garnered significant attention due to their compounding effects on women's health, particularly among vulnerable populations. The interplay between these infections exacerbates disease progression and challenges in healthcare management.

### HIV Epidemiology and Prevention

Degenhardt et al. (2010) emphasized the importance of integrated approaches for preventing HIV transmission among people who inject drugs. These approaches include harm reduction strategies such as needle exchange programs and methadone maintenance therapy, which have shown significant success in reducing new infections. Birrell et al. (2013) analyzed HIV incidence among men who have sex with men in England and Wales, highlighting the persistent high rates despite widespread ART availability, necessitating tailored interventions.

### HIV and HPV Coinfections

The interaction between HIV and HPV is a crucial area of study due to its impact on cervical cancer risk. Baay et al. (2005) reported that HIV-positive women exhibit higher persistence rates of oncogenic HPV genotypes, making them more vulnerable to cervical dysplasia and malignancies. Similarly, Ho et al. (1998) detailed the natural history of HPV infections, underscoring the influence of immune suppression on infection persistence and progression.

### Immunological and Cellular Mechanisms

Maertens et al. (2003) explored the molecular mechanisms of HIV integration into host cells, identifying LEDGF/p75 as a key protein in targeting HIV-1 integrase to chromosomal sites. This insight is critical for developing antiretroviral therapies. Klein et al. (2013) investigated the role of somatic mutations in the immunoglobulin framework, which are necessary for broad and potent neutralization of HIV-1, highlighting advancements in vaccine research.

### Sociobehavioral and Structural Influences

Jewkes et al. (2010) demonstrated the role of intimate partner violence and relationship inequities in increasing HIV risk among young women in South Africa. Their findings underline the necessity for addressing sociocultural determinants of health in combating the epidemic. Polis et al. (2013) reviewed the association between hormonal contraceptive use and HIV acquisition, providing evidence for the need for safer contraceptive options in HIV-prevalent regions.

### Global HIV Burden and Intervention Strategies

Granich et al. (2013) analyzed trends in AIDS-related mortality and ART coverage, noting substantial progress in high-burden countries but cautioning against funding stagnation that threatens to reverse these gains. Murray et al. (2013) conducted a systematic analysis of the global burden of HIV, tuberculosis, and malaria, offering insights into geographic disparities in disease impact and resource allocation.

### Role of Concurrent Infections

Tanser et al. (2011) investigated the effect of concurrent sexual partnerships on HIV transmission in high-prevalence rural South African settings, highlighting behavioral interventions as a key component of HIV prevention. The co-occurrence of HIV and other sexually transmitted infections, such as HPV, further complicates the epidemiology of these diseases, as demonstrated by the increased malignancy risk in coinfecting individuals.

### Implications for Public Health

The synergistic effect of HIV and HPV in immunocompromised populations underscores the importance of integrated screening, vaccination, and treatment programs. HIV-related immunosuppression exacerbates HPV persistence and progression to malignancy, as evidenced by findings from Baay et al. (2005) and others. Addressing these challenges requires a holistic approach, combining medical, behavioral, and structural interventions to reduce the dual burden of these infections.

The literature reveals the complex dynamics of HIV and HPV coinfections, highlighting gaps in prevention, treatment, and policy frameworks. Continued research into their epidemiological trends, molecular mechanisms, and sociocultural

determinants is vital for advancing global health outcomes and achieving ambitious goals such as the UNAIDS 90-90-90 targets.

### III. METHODOLOGY

#### Study Population and Specimen Collection

This study was conducted in 2015 at R.D. Gardi Medical College, Ujjain, Madhya Pradesh, with samples collected from a women's detention facility. Upon admission, detainees were tested for HIV-I/II antibodies. Those infected were segregated from their HIV-negative counterparts. The prevalence of HIV infection among incarcerated women was 8.5% in 2007. Of approximately 1,400 inmates, over 75% of incarcerations were directly or indirectly associated with illicit drug use.

During the 2008 annual Pap smear screening, 76 HIV-positive women were invited for testing after being provided with complete information about HPV. An equal number of age-matched ( $\pm 3$  years) HIV-negative participants were enrolled consecutively after obtaining informed consent. Participants completed self-administered questionnaires, underwent thin-preparation Pap smear testing, and provided samples for HPV genotyping. CD4+ T-cell counts were measured using flow cytometry.

#### HIV Serologic Determination

Initial testing for HIV-I/II antibodies was performed using a microparticle enzyme immunoassay (HIV 1/2 gO, Abbott Diagnostic Division). Samples that tested positive were reanalyzed in duplicate, and results were confirmed using the Western blot HIV-1 and HIV-2 assay.

#### Cervical Cytology

Thin-preparation Pap smears were prepared and sent to a certified laboratory. Two cytopathology technicians and two cytopathologists performed a blind evaluation of the Pap smears. Results were categorized according to the 2001 Bethesda System terminology. Cervical cells were preserved in PreservCyt solution for further analysis.

#### Epidemiology

The HIV epidemic originated from zoonotic infections with simian immunodeficiency viruses in African primates, likely through bushmeat hunting. HIV-1 was transmitted from apes, and HIV-2 from sooty mangabey monkeys. Four groups of HIV-1 exist: M, N, O, and P. Group M is the primary driver of the global HIV pandemic, while groups N, O, and P are restricted to West Africa.

#### HIV-1 Transmission

The primary risk factor for sexual transmission of HIV-1 is the viral load in plasma. A 2.4-fold increased risk of transmission occurs with each 1 log<sub>10</sub> increase in HIV-1 RNA copies per mL of plasma. Acute HIV infection, characterized by high viral loads in the initial months, is a significant driver of HIV epidemics. A reduction in viral load of 0.7 log<sub>10</sub> is estimated to reduce transmission risk by 50%.

#### HIV Lifecycle and Immune Response

HIV primarily targets activated CD4+ T lymphocytes by interacting with CD4 and chemokine coreceptors (CCR5 or CXCR4). Other cells, including resting CD4+ T cells, monocytes, macrophages, and dendritic cells, can also be infected. In rare cases, CD4-independent infection occurs, such as in astrocytes and renal epithelial cells.

#### Mother-to-Child Transmission

Significant progress has been made in reducing perinatal HIV-1 transmission risk over the past two decades. Without interventions, the transmission risk at delivery is approximately 25%, with most cases occurring after 36 weeks of gestation or during intrapartum. HIV-1 transmission occurs at a rate of 8.9 per 100 child-years of breastfeeding.

#### IV. RESULTS

This study demonstrated that HIV serostatus significantly influences the persistence and detection of oncogenic HPV infection among female illicit drug users. The findings showed higher rates of persistent oncogenic HPV DNA in HIV-positive women compared to their HIV-negative counterparts.

The study highlighted that the immunocompromised status associated with HIV, as indicated by lower CD4+ T-cell levels, contributes to the persistence of HPV infections. However, the mechanisms by which immunosuppression increases the risks of HPV-related diseases remain poorly understood. While CD4+ T-cell counts served as markers for general immunosuppression, the study lacked specific markers for HPV-specific immunity.

The prevalence of oncogenic HPV was notably higher in the HIV-positive group, underlining the role of HIV in creating an environment conducive to HPV persistence and its progression to malignancies. These results emphasize the need for targeted interventions to mitigate the compounded risks faced by women coinfecting with HIV and HPV.

#### V. DISCUSSION

The findings from this study provide significant insights into the complex interplay between HIV and HPV coinfections, emphasizing the compounded challenges faced by women who are coinfecting. The persistence of oncogenic HPV in HIV-positive women underscores the critical role of immunosuppression in exacerbating the risks of HPV-related diseases, including cervical malignancies.

The study's results align with existing literature highlighting that lower CD4+ T-cell counts in HIV-positive individuals contribute to the persistence of HPV infections. This immunological compromise provides a favorable environment for HPV to evade immune surveillance, potentially accelerating the progression to precancerous and cancerous states. However, the absence of HPV-specific immunity markers in the study leaves room for further exploration of the precise mechanisms driving this persistence.

Additionally, the demographic focus on female illicit drug users illuminates the intersectionality of social, behavioral, and biological factors in shaping health outcomes. The high prevalence of oncogenic HPV in this group calls attention to the necessity of targeted health interventions that address both HIV management and HPV prevention. Comprehensive strategies, such as integrating HPV vaccination programs with routine HIV care and enhancing cervical cancer screening accessibility, are pivotal for reducing the dual burden of these infections.

The implications of these findings extend beyond clinical management to public health policies. Efforts to combat the compounded impact of HIV and HPV require a multifaceted approach, combining medical advancements, community engagement, and structural interventions to tackle social determinants of health. The demonstrated success of harm reduction programs in other contexts, such as Taiwan's needle exchange initiatives, serves as a valuable model for addressing the behavioral and structural contributors to coinfection risks.

Future research should prioritize longitudinal studies to explore the dynamic interactions between HIV and HPV over time and investigate the potential role of emerging therapies in mitigating HPV-related malignancy risks in HIV-positive populations. By addressing these gaps, the global health community can move closer to achieving ambitious goals like the UNAIDS 90-90-90 targets and improving the quality of life for vulnerable groups.

The study reinforces the urgency of integrating HIV and HPV management efforts into comprehensive women's health initiatives. Through sustained research, investment, and coordinated actions, significant progress can be made toward mitigating the dual burden of these infections and reducing their impact on global health.

#### VI. CONCLUSION

HIV continues to be a significant contributor to the global disease burden, particularly in regions such as sub-Saharan Africa. The introduction and widespread use of antiretroviral therapy (ART) have transformed the epidemiology of HIV by reducing AIDS-related deaths and decreasing HIV transmission rates through viral suppression. However, the

persistence of HIV incidence among specific populations, such as men who have sex with men, despite high ART coverage, indicates the need for more tailored prevention strategies.

The study demonstrated a strong association between HIV serostatus and persistent oncogenic HPV infections among female illicit drug users. HIV-related immunosuppression, as indicated by reduced CD4+ T-cell levels, plays a pivotal role in the persistence of HPV infections and the increased risk of HPV-related malignancies. These findings highlight the necessity for comprehensive health programs addressing both HIV and HPV infections, including vaccination, regular screening, and robust treatment protocols.

To achieve global goals, such as the UNAIDS 90-90-90 targets and the elimination of HIV/AIDS as a public health threat by 2030, sustained funding and a coordinated global effort are essential. Targeted prevention strategies, expanded access to ART, and the integration of HIV and HPV management programs are critical to mitigating the dual burden of these infections and improving health outcomes for vulnerable populations.

## REFERENCES

1. Baay, M. F., Kjetland, E. F., Ndhlovu, P. D., Deschoolmeester, V., Mduluzi, T., Gomo, E., ... & Gudmundsdottir, H. (2005). Human papillomavirus in a rural community in Zimbabwe: The impact of HIV co-infection on HPV genotype distribution. *Journal of Medical Virology*, 73(3), 481–485.
2. Das, Priyanka & Srivastav, Alok Kumar (2021). A Study on Molecular Targeted Approaches To Cancer Therapy And The Role of Chalcones In Chemoprevention. *European Journal of Molecular & Clinical Medicine*, 8(3):3254-3267.
3. Pathak, N., & Srivastav, A. K. (2024). Antimicrobial Activity of Selected Medicinal Plants from Around Ujjain City, India. *International Journal of Emerging Research in Engineering, Science, and Management*, 3(4), 57-61.
4. Srivastav, A. K., Das, P., Jaiswal, P., Parashar, V. (2024). CRISPR-Cas Systems for Targeted Therapy in Multidrug-Resistant Infections: A New Frontier in Medical Microbiology. *International Journal of Innovative Research in Science, Engineering and Technology*, 13(11), 18332-18340.
5. Rather, A. H., & Srivastav, A. K. (2020). An analytical study on genetic variability and hydrogen (H<sub>2</sub>) production from cyanobacteria. *European Journal of Molecular & Clinical Medicine*, 7(9), 3723-3735.
6. Pal, M., & Srivastav, A. K. (2021). Prevalence of extended spectrum beta-lactamases (ESBL) producers among gram-negative bacilli in urinary tract infection (UTI). *Advances of Bioresearch*, 12(5), 49-57.
7. Birrell, P. J., Gill, O. N., Delpech, V. C., Brown, A. E., Desai, S., Chadborn, T. R., ... & De Angelis, D. (2013). HIV incidence in men who have sex with men in England and Wales 2001–10: A nationwide population study. *The Lancet Infectious Diseases*, 13(4), 313–318.
8. Srivastav, A. K., & Janahiraman, V. (2019). Microbial Synthesis of Hyaluronan and Its Biomedical Applications. *International Journal of Scientific Research And Review*, 8(5), 852-863.
9. Rather, A. H., & Srivastav, A. K. (2021). A study on various parameters affecting hydrogen production of *Cyanothece 51142*. *Plant Cell Biotechnology and Molecular Biology*, 22(41&42), 61-74.
10. Pathak, N., & Srivastav, A. K. (2020). Phytochemical screening and characterization of *Withania somnifera* for their antimicrobial and antioxidant activity. *European Journal of Molecular & Clinical Medicine*, 7(9), 3287-3298.
11. Degenhardt, L., Mathers, B., Wirtz, A. L., Wolfe, D., Kamarulzaman, A., Carrieri, M. P., ... & Beyrer, C. (2010). Prevention of HIV infection for people who inject drugs: Why individual, structural, and combination approaches are needed. *The Lancet*, 376(9737), 285–301.
12. Srivastav, A. K., & Janahiraman, V. (2019). Study on Microbial Production of Hyaluronic Acid. *Research Review International Journal of Multidisciplinary*, 4(5), 231-233.
13. Das, P., Jaiswal, P., Parashar, V. (2024). Molecular Mechanisms of Antimicrobial Resistance in Gastrointestinal Pathogens: Challenges and Opportunities. *International Journal of Innovative Research in Science, Engineering and Technology*, 13(12), 20463- 20470.
14. Granich, R., Gupta, S., Hersh, B., et al. (2013). Trends in AIDS deaths, new infections, and ART coverage in the top 30 countries with the highest AIDS mortality burden; 1990–2013. *The Lancet Global Health*, 1(1), e26–e30.
15. Pathak, N., & Srivastav, A. K. (2021). Phytochemical analysis and characterization of *Moringa oleifera* for its antimicrobial and antioxidant activity. *International Journal of Botany Studies*, 6(3), 387-390.
16. Ho, G. Y., Bierman, R., Beardsley, L., Chang, C. J., & Burk, R. D. (1998). Natural history of cervicovaginal papillomavirus infection in young women. *New England Journal of Medicine*, 338(7), 423–428.

17. Srivastav, A. K., & Suriyakala, P. C. (2023). Biotechnological production and purification of hyaluronic acid from *Streptococcus zooepidemicus*. *Journal of Pharmaceutical Negative Results*, 14(2), 78-83.
18. Jewkes, R. K., Dunkle, K., Nduna, M., & Shai, N. (2010). Intimate partner violence, relationship power inequity, and incidence of HIV infection in young women in South Africa: A cohort study. *The Lancet*, 376(9734), 41–48.
19. Srivastav, A. K., & Suriyakala, P. C. (2022). Hyaluronic acid generated by *Streptococcus zooepidemicus* is recovered utilizing PEG-citrate aqueous two phase systems. *Journal of Pharmaceutical Negative Results*, 13(1), 100-108.
20. Joshi, D., O’Grady, J., Dieterich, D., Gazzard, B., & Agarwal, K. (2011). Increasing burden of liver disease in patients with HIV infection. *The Lancet*, 377(9772), 1198–1209.
21. Srivastav, A. K., & Suriyakala, P. C. (2021). Chemical mutants enable the photoresponsive synthesis of hyaluronic acid from *Streptococcus equi*. *Natural Volatiles & Essential Oils*, 8(3), 371-381.
22. Klein, F., Mouquet, H., Dosenovic, P., Scheid, J. F., Scharf, L., & Nussenzweig, M. C. (2013). Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. *Cell*, 153(1), 126–138.
23. Srivastav, A. K., & Das, P. (2024). Biopharmaceutical production in plant-based systems: Current status and future prospects. *International Journal of Zoological Investigations*, 10(1), 157-167.
24. Ladell, K., Price, D. A., & McMichael, A. J. (2013). A molecular basis for the control of preimmune escape variants by HIV-specific CD8+ T cells. *Immunity*, 38(3), 425–436.
25. Srivastav, A. K., Das, P., Jaiswal, P., Parashar, V. (2024). Plant Pathology in the Age of Climate Change: Challenges and Adaptations. *International Journal of Innovative Research in Science, Engineering and Technology*, 13(10), 17112-17120.
26. Maertens, G., Cherepanov, P., Pluymers, W., Busschots, K., De Clercq, E., Debyser, Z., & Engelborghs, Y. (2003). LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. *Journal of Biological Chemistry*, 278(37), 33528–33539.
27. Das, Priyanka & Srivastav, Alok Kumar (2022). A Comparative Study on the Ecological Significance of Temple Ponds in the Indian State of Kerala. *International Journal of Multidisciplinary Educational Research*, 11(8):75-79.
28. Murray, C. J. L., Ortblad, K. F., Guinovart, C., et al. (2013). Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. *The Lancet*, 384(9947), 1005–1070.
29. Srivastav, A. K., & Das, P. (2015). To Study the Production and Standardization of Veterinary Vaccines. *International Journal of Science and Research*, 4(6), 2331-2337.
30. Naghavi, M., Wang, H., Lozano, R., et al. (2013). Global, regional, and national age-sex-specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. *The Lancet*, 385(9963), 117–171.
31. Srivastav, Alok Kumar & Das, Priyanka (2014). To Study the Formulation of Niosome of Ofloxacin and Its Evaluation for Efficacy of Anti-Microbial Activity. *International Journal of Innovative Research in Science Engineering and Technology*, 3(12):17958-17965.
32. Polis, C. B., Curtis, K. M., Hannaford, P. C., Phillips, S. J., Chipato, T., & Kiarie, J. N. (2013). Use of hormonal contraceptives and HIV acquisition in women: A systematic review of the epidemiological evidence. *The Lancet Infectious Diseases*, 13(9), 797–808.
33. Srivastav, Alok Kumar & Das, Priyanka (2015). A Comparative Study of the Effect of Ampicillin and Tetracyclin on Bacterial Culture by Measuring the Zone of Inhibition. *International Journal of Pharmaceutical Research and Bio- Science*, 4(1):277-285.
34. Tanser, F., Barnighausen, T., Hund, L., Garnett, G. P., McGrath, N., & Newell, M. L. (2011). Effect of concurrent sexual partnerships on the rate of new HIV infections in a high-prevalence, rural South African population: A cohort study. *The Lancet*, 378(9787), 247–255.



INTERNATIONAL  
STANDARD  
SERIAL  
NUMBER  
INDIA



# INTERNATIONAL JOURNAL OF INNOVATIVE RESEARCH

IN SCIENCE | ENGINEERING | TECHNOLOGY

 9940 572 462  6381 907 438  [ijirset@gmail.com](mailto:ijirset@gmail.com)



[www.ijirset.com](http://www.ijirset.com)

Scan to save the contact details